Citarinostat

N/A

Report date: 2024/10/04 20:00:32
NME

Base Information

Drug NameCitarinostat
Drug Alias NameHDAC-IN-2CC-96241ACY-241
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase 6 inhibitors
TargetsHistone deacetylase 6
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungMultiple Myeloma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyFrance +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAcetylon
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCelgene Corp
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungMultiple Myeloma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A